Although β3-AR agonists have demonstrated significant anti-obesity effects in animal models (Abdul Sater et al, 2022), their safety and efficacy in humans remain to be thoroughly investigated. This evidence concerns the gene ADRB3 and obesity due to melanocortin 4 receptor deficiency.